The central question about gene editing for cholesterol was never whether it works. It was whether it lasts. Investigators have now followed patients for a full year after a single infusion and reported that the effect held.
Among participants who received the highest dose of the experimental CRISPR-Cas9 therapy CTX310, LDL cholesterol was 52.5 percent below baseline, and triglycerides were 47.8 percent lower at 12 months. No serious adverse events related to the therapy were recorded during that year. The results were presented at the European Society of Cardiology Congress and published simultaneously in the New England Journal of Medicine, according to Cleveland Clinic, whose cardiologists led the study.
Earlier results from the same trial, covering roughly two months of follow-up, were reported last November. The open question then was whether the effect would fade.
The trial enrolled 15 patients. That number belongs at the front of this story, not buried at the end. Fifteen people, in a Phase 1a open-label dose escalation study built to test safety, and the headline figures come from the four who received the highest dose.
The Biology Borrowed from a Naturally Protected Population
CTX310 is delivered as a one-time infusion carrying CRISPR editing machinery to the liver, where it switches off a gene called ANGPTL3. That gene produces a protein that blocks the breakdown of LDL cholesterol and triglycerides. Turning it off lets the body clear both more efficiently.
The approach copies something nature already produced. People born with a defective ANGPTL3 gene have low LDL and triglycerides and unusually little cardiovascular disease. The therapy attempts to reproduce that protection in a liver that was not born with it.
The editing itself looks deep and durable. At the top dose, circulating ANGPTL3 fell by a mean of 79 percent, reaching 89 percent in one participant, and stayed down at a year.
"Building upon the initial data presented in November 2025, the durability of the lipid-lowering effect was impressive," said Cleveland Clinic cardiologist Luke Laffin, the study's first author. "It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment. We look forward to continuing to investigate this therapy in a larger number of patients."
Doses ranged from 0.1 to 0.8 milligrams per kilogram, given after pretreatment with corticosteroids and antihistamines. Most participants were already on statins or ezetimibe, and 40 percent were taking PCSK9 inhibitors, so the reductions came on top of existing therapy.
The Gap Between a Lipid Number and a Prevented Heart Attack
Lowering LDL is not the same as preventing heart attacks and strokes. Decades of statin research established that link for statins specifically, through trials enrolling tens of thousands of people and tracking cardiovascular events over years. No such evidence exists for CTX310. This trial measured blood lipids, not outcomes.
The permanence cuts both ways. If an unexpected problem emerges, there is no discontinuing the treatment. Participants will be monitored for an additional 15 years, the standard the Food and Drug Administration applies to gene editing therapies. That requirement exists precisely because the long term effects of permanent genetic modification are not yet characterized in humans.
Funding and disclosure belong in the record. The study was funded by CRISPR Therapeutics, the company developing the drug, and Laffin's institution has received research funding from the company. Neither fact invalidates the results, but both belong in any assessment of them. Senior author Steven Nissen framed the appeal in the company's own announcement, calling a one-time treatment with this degree of durability a potentially meaningful advance in managing lifelong lipid disorders.
The Patients This Could Reach First, and When
Nobody currently taking a statin should expect this as an option soon, and nobody should stop a prescribed cholesterol medication because of these results.
The population most likely to benefit first is narrow: people with severe, genetically driven lipid disorders that do not respond adequately to existing drugs. The trial enrolled four such groups, including homozygous and heterozygous familial hypercholesterolemia, severe hypertriglyceridemia, and mixed dyslipidemia. For someone facing a lifetime of injections, apheresis or early cardiovascular events, a durable one time treatment would be a genuine change. That group is small.
Cost and access would follow the pattern of other gene therapies, which have launched at prices reaching seven figures and required specialized centers. Coverage for a permanent intervention with no outcome data would be contested, and patients far from academic medical centers would wait longest even after any approval.
Existing options remain the practical answer for the overwhelming majority. Statins, ezetimibe, PCSK9 inhibitors, and bempedoic acid are approved, backed by large outcome trials, and available now. Anyone whose cholesterol is uncontrolled has more to gain from a conversation about those than from waiting on gene editing. Adherence is a more common problem than drug failure, and it is addressable.
There is also a question the trial cannot answer about preference. A permanent edit appeals differently to a 30 year old with a severe inherited disorder than to a 65 year old whose cholesterol responds to a daily tablet.
Regulatory Distance and the Next Readouts
CTX310 is investigational. It has not been approved by the FDA for any use, and the path from a 15-patient Phase 1a study to approval runs through larger trials, then outcome trials, then regulatory review. Each stage takes years, and therapies fail at every one.
The company is already running Phase 1b trials in the United States and abroad, and has said it expects to share data from a severe hypertriglyceridemia group later this year. Watch for enrollment details in larger studies, longer safety follow-up on the original 15 participants, and whether extended liver enzyme monitoring reveals anything.
The honest reading of this week's news: an early trial answered its durability question convincingly, in a very small group, with company funding, and without touching the question that ultimately matters, which is whether editing this gene prevents cardiovascular events. That is genuine progress in a field where durability was a live doubt. It is not a treatment anyone can get, and it does not change what a person with high cholesterol should do this month.
Key Questions Answered
What did the one-year results show? At the highest dose, LDL cholesterol was 52.5 percent below baseline, and triglycerides were 47.8 percent lower 12 months after a single infusion, with circulating ANGPTL3 down about 79 percent. No serious adverse events related to the therapy occurred during that year.
How many people were in the study? Fifteen. It was a Phase 1a first in human, open label dose escalation trial designed primarily to test safety, and the headline figures come from the four participants at the highest dose.
Does this mean fewer heart attacks? Not established. The trial measured cholesterol and triglyceride levels, not cardiovascular events. Whether editing this gene reduces heart attacks and strokes requires much larger and longer trials.
Is the treatment permanent? That is the intent. The edit to the ANGPTL3 gene in liver cells is designed to be durable, which is why participants will be followed for an additional 15 years, as the FDA requires for gene editing therapies.
Who funded the research? CRISPR Therapeutics funded the study, and the first author's institution has received research funding from the company. That does not invalidate the findings, but it belongs in any assessment of them.
Could this replace statins? Not now and not soon. CTX310 is investigational and unapproved. Statins and other approved lipid-lowering drugs have large outcome trials behind them and remain the appropriate treatment for people who need cholesterol lowering today.
